NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Adam SS, McDuffie JR, Lachiewicz PF, et al. Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement [Internet]. Washington (DC): Department of Veterans Affairs; 2012 Dec.

Cover of Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement

Comparative Effectiveness of Newer Oral Anticoagulants and Standard Anticoagulant Regimens for Thromboprophylaxis in Patients Undergoing Total Hip or Knee Replacement [Internet].

Show details

REFERENCES

1.
Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e278S–325S. [PMC free article: PMC3278063] [PubMed: 22315265]
2.
Mont MA, Jacobs JJ, Boggio LN, et al. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Am Acad Orthop Surg. 2011;19(12):768–76. [PubMed: 22134209]
3.
Hill J, Treasure T. Reducing the risk of venous thromboembolism (deep vein thrombosis and pulmonary embolism) in inpatients having surgery: summary of NICE guidance. BMJ. 2007;334(7602):1053–4. [PMC free article: PMC1871784] [PubMed: 17510154]
4.
Friedman RJ, Gallus A, Gil-Garay E, et al. Practice patterns in the use of venous thromboembolism prophylaxis after total joint arthroplasty—insights from the Multinational Global Orthopaedic Registry (GLORY) Am J Orthop (Belle Mead NJ) 2010;39(9 Suppl):14–21. [PubMed: 21290027]
5.
Binns M, Pho R. Femoral vein occlusion during hip arthroplasty. Clin Orthop Relat Res. 1990;(255):168–72. [PubMed: 2189628]
6.
Clark C, Cotton LT. Blood-flow in deep veins of leg. Recording technique and evaluation of methods to increase flow during operation. Br J Surg. 1968;55(3):211–4. [PubMed: 5637094]
7.
Planes A, Vochelle N, Fagola M. Total hip replacement and deep vein thrombosis. A venographic and necropsy study. J Bone Joint Surg Br. 1990;72(1):9–13. [PubMed: 2298803]
8.
Sharrock NE, Go G, Harpel PC, et al. The John Charnley Award. Thrombogenesis during total hip arthroplasty. Clin Orthop Relat Res. 1995;(319):16–27. [PubMed: 7554626]
9.
Sobieraj DM, Coleman CI, Tongbram V, et al. Venous Thromboembolism in Orthopedic Surgery, Comparative Effectiveness Review No. 49. Rockville, MD: Agency for Healthcare Research and Quality; Mar, 2012. [Accessed November 7, 2012]. (Prepared by the University of Connecticut/Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). AHRQ Publication No 12-EHC020-EF. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
10.
Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2005;87(9):2097–112. [PubMed: 16140827]
11.
Molnar RB, Jenkin DE, Millar MJ, et al. The Australian arthroplasty thromboprophylaxis survey. J Arthroplasty. 2012;27(2):173–9. [PubMed: 21752576]
12.
Ettema HB, Mulder MC, Nurmohamed MT, et al. Dutch orthopedic thromboprophylaxis: a 5-year follow-up survey. Acta Orthop. 2009;80(1):109–12. [PMC free article: PMC2823229] [PubMed: 19234891]
13.
Hirsh J, Levine MN. Low molecular weight heparin: laboratory properties and clinical evaluation. A review. Eur J Surg Suppl. 1994;(571):9–22. [PubMed: 7519092]
14.
Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997;337(10):688–98. [PubMed: 9278467]
15.
Turpie AG. Pentasaccharide Org31540/SR90107A clinical trials update: lessons for practice. Am Heart J. 2001;142(2 Suppl):S9–15. [PubMed: 11479485]
16.
Fareed J, Thethi I, Hoppensteadt D. Old versus new oral anticoagulants: focus on pharmacology. Annu Rev Pharmacol Toxicol. 2012;52:79–99. [PubMed: 21819239]
17.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. [PubMed: 19631508]
18.
Montori VM, Wilczynski NL, Morgan D, et al. Optimal search strategies for retrieving systematic reviews from MEDLINE: analytical survey. BMJ. 2005;330(7482):68. [PMC free article: PMC543864] [PubMed: 15619601]
19.
Shojania KG, Bero LA. Taking advantage of the explosion of systematic reviews: an efficient MEDLINE search strategy. Eff Clin Pract. 2001;4(4):157–62. [PubMed: 11525102]
20.
Neumann I, Rada G, Claro JC, et al. Oral direct factor Xa inhibitors versus lowmolecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement a systematic review and meta-analysis. Ann Intern Med. 2012;156(10):710–719. [PubMed: 22412038]
21.
Loke YK, Kwok CS. Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. J Clin Pharm Ther. 2011;36(1):111–24. [PubMed: 21198726]
22.
Ringerike T, Hamidi V, Hagen G, et al. Thromboprophylactic treatment with rivaroxaban or dabigatran compared with enoxaparin or dalteparin in patients undergoing elective hip- or knee replacement surgery. Report from NOKC nr 13 - 2011. Health Technology Assessment (HTA) 2011
23.
Gómez-Outes A, Terleira-Fernández AI, Suárez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344 [PMC free article: PMC3375207] [PubMed: 22700784]
24.
Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94(8):746–7. [PMC free article: PMC3326685] [PubMed: 22517391]
25.
Marinopoulos SS, Dorman T, Ratanawongsa N, et al. Effectiveness of continuing medical education. Evid Rep Technol Assess (Full Rep) 2007;(149):1–69. [PubMed: 17764217]
26.
Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896–900. [PubMed: 10584742]
27.
Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10. [PMC free article: PMC1810543] [PubMed: 17302989]
28.
Mills EJ, Ioannidis JP, Thorlund K, et al. How to use an article reporting a multiple treatment comparison meta-analysis. JAMA. 2012;308(12):1246–53. [PubMed: 23011714]
29.
Agency for Healthcare Research and Quality. Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; [Accessed August 1, 2012]. Available at: www​.effectivehealthcare​.ahrq.gov/search-for-guides-reviews-and-reports​/?pageaction​=displayproduct&mp​=1&productID=318.
30.
Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence--imprecision. J Clin Epidemiol. 2011;64(12):1283–93. [PubMed: 21839614]
31.
Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ. 2008;336(7653):1106–10. [PMC free article: PMC2386626] [PubMed: 18483053]
32.
Cao YB, Zhang JD, Shen H, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010;66(11):1099–108. [PubMed: 20812009]
33.
Huang J, Cao Y, Liao C, et al. Apixaban versus enoxaparin in patients with total knee arthroplasty. A meta-analysis of randomised trials. Thromb Haemost. 2011;105(2):245–53. [PubMed: 20941455]
34.
Turun S, Banghua L, Yuan Y, et al. A systematic review of rivaroxaban versus enoxaparin in the prevention of venous thromboembolism after hip or knee replacement. Thromb Res. 2011;127(6):525–34. [PubMed: 21397931]
35.
Alves C, Batel-Marques F, Macedo AF. Apixaban and Rivaroxaban Safety After Hip and Knee Arthroplasty: A Meta-Analysis. J Cardiovasc Pharmacol Ther. 2011 [PubMed: 22134134]
36.
Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765–75. [PubMed: 18579811]
37.
Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372(9632):31–9. [PubMed: 18582928]
38.
Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776–86. [PubMed: 18579812]
39.
Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673–80. [PubMed: 19411100]
40.
Eriksson BI, Dahl OE, Buller HR, et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103–11. [PubMed: 15634273]
41.
Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–91. [PubMed: 9250266]
42.
Robinson KA, Saldanha IJ, Mckoy NA. Frameworks for Determining Research Gaps During Systematic Reviews, Methods Future Research Needs Report No. 2. Rockville, MD: Agency for Healthcare Research and Quality; Jun, 2011. [Accessed May 22, 2012]. (Prepared by the Johns Hopkins University Evidence-based Practice Center under Contract No. HHSA 290-2007-10061-I). AHRQ Publication No 11-EHC043-EF. Available at: www​.effectivehealthcare​.ahrq.gov/reports/final.cfm.
43.
Myers E, McBroom AJ, Shen L, et al. Value-of-Information Analysis for Patient-Centered Outcomes Research Prioritization. Report prepared by the Duke Evidence-based Practice Center. Patient-Centered Outcomes Research Institute. Mar, 2012.
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (850K)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...